Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

Prostate Cancer Clinical Trial

— SetPace  

Official title:

A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00770822
• Other study ID #: FSI-002
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 2007
• Est. completion date: December 2020

Study information

• Verified date: April 2019
• Source: SonaCare Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will compare high intensity focused ultrasound to standard brachytherapy in the treatment of primary, organ confined prostate cancer.

Description:

The proposed study is a prospective, non-randomized concurrently controlled study. The active treatment arm uses the HIFU procedure with the Sonablate device. The control arm uses the brachytherapy procedure. The safety and effectiveness of the Sonablate arm will be compared with the brachytherapy arm. The control arm of the study will be conducted at clinical sites different from the Sonablate arm.

Other known NCT identifiers

• NCT00485381

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 466
• Est. completion date: December 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• T1c or T2a carcinoma of the prostate confirmed by biopsy;

• life expectancy of 5(five) years or more;

• prostate biopsy with 10(ten) or more core biopsies;

• Gleason score of 6(six) or less;

• serum Prostate Specific Antigen (PSA) of 10(ten)ng/ml or less;

• prostate volume of less than 40(Forty)cc;

• distance from the Anterior capsule surface to the Posterior capsule surface (AP Diameter) of 40(Forty)cm or less;

• informed consent for the treatment study through 24 months post-treatment follow-up

Exclusion Criteria:

• men who have had previous definitive treatment for prostate cancer;

• evidence of metastatic disease and/or a previous positive bone-scan, previous diagnosis or treatment for cancer within the last 5(five) years;

• prior hormonal therapy for prostate cancer (including bilateral orchiectomy);

• inability to tolerate a transrectal ultrasound;

• active urinary tract infection;

• functional bladder problems;

• prior significant rectal surgery;

• intra-prostatic calcifications greater than 1(One)cm in diameter;

• interest in future fertility;

• prostatic surgery/procedure (except biopsy) within 1(One) year;

• large median lobe of the prostate;

• use of medications that can affect PSA within 2(Two) months (e.g. finasteride, saw palmetto);

• current bladder cancer, urethral stricture, or bladder neck contracture;

• urinary tract and/or rectal fistula;

• rectal fibrosis/stenosis;

• anomaly of the rectal anatomy or mucus membrane;

• prostate seroma/abcess;

• prostatitis;

• compromised renal function or upper urinary tract disease secondary to urinary obstruction;

• bleeding disorders/coagulopathy based on measures of PT and PTT;

• implant in the prostate or within 1(One)cm of the prostate;

• zip code of the primary residence of the subject is greater than 200(Two hundred) miles from the clinical site or transportation that would hinder the completion of the study

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• HIFU (Sonablate® 500)
High Intensity Focused Ultrasound
• Brachytherapy
Standard of care

Locations

Country	Name	City	State
United States	Brachytherapy Site: Urology Centers of Alabama	Birmingham	Alabama
United States	HIFU Site: Southeast Urology Network	Memphis	Tennessee
United States	Brachytherapy Site: Grand Strand Urology	Myrtle Beach	South Carolina
United States	Brachytherapy Site: Specialists in Urology	Naples	Florida
United States	HIFU Site: Urology Associates	Nashville	Tennessee
United States	HIFU Site: Urology of San Antonio	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
SonaCare Medical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be the absence of biochemical failure, which is defined as a rise of 2.0 ng/mL or more above the PSA nadir and negative biopsy at 24 months.		24 Months